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(DVT). It needs a much shorter course of anticoagulation. Still,
pulmonary embolism can occur and lack of treatment may cause
extension of the thrombosed vein segment. Thrombus extension
from the saphenous vein into the femoral vein can occur not only
in spontaneous saphenous thrombophlebitis but also after laser or
radiofrequency ablation, and after foam sclerotherapy or open high
ligation of the saphenous vein. Its incidence was 10% (3 of 30) in
the small saphenous vein after 30 endovenous laser therapy, as
reported recently by Gibson et al.5 Gradman et al6 documented
pulmonary embolism after EVLT. In 7611 EVLT procedures,
Kabnick7 observed DVT in 0.27% and pulmonary embolism in
0.023%. When foam sclerotherapy was used for saphenous abla-
tion, the incidence of DVT was 2.9% (16 of 558) in the series
reported by Wright and Rush.8 Hingorani et al9 reported an incidence
of DVT of 16% after radiofrequency ablation, and Merchant et al10
reported an incidence of about 1%.
We must remain vigilant and should do everything to prevent,
diagnose, and treat early thrombotic complications of endovenous
procedures.
Alessandra Puggioni, MD
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Regarding “3-Hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors reduce the risk of perioperative
stroke and mortality after carotid endarterectomy”
We read with great interest the recent article by McGirt et al
(J Vasc Surg 2005;42:829-36). Recently, several trials reported
beneficial effects of statins on perioperative cardiovascular out-
come in patients undergoing noncardiac vascular surgery. This
effect was ascribed to the pleiotropic ability of statins to “stabilize”
vulnerable (coronary) plaques.1,2 The study of McGirt et al is a
logical next step in clarifying the beneficial effects of statins in
vascular surgical patients.
The investigators report the outcome of 1566 consecutive pa-
tients who underwent carotid endarterectomy (CEA) at a single
academic center. A total of 657 patients who received statin therapy
for at least 1 week before surgery were compared with 909 patients
not on statin therapy. They concluded that statin use is associatedwith
a threefold-reduced risk of stroke and a fivefold-reduced risk of
perioperative death.We agree that statins may improve outcome after
CEA, but their report raises several questions.
First, the study sample ofMcGirt et al is rather heterogeneous.
Although the logistic regression model included a variable “symp-
tomatic carotid stenosis,” it is questionable whether symptomatic
and asymptomatic patients may be included in one model. Re-
cently, Kennedy et al3 published a comparable study that included
3238 patients undergoing CEA. That study clearly showed a more
pronounced beneficial effect of statins in symptomatic patients.
Because statins are thought to stabilize vulnerable plaques, it seems
logical to consider symptomatic (a proven vulnerable lesion) and
asymptomatic (no proof of a vulnerable lesion) as two entities. This
might especially apply to retrospective studies where not all radio-
graphic data on plaque composition are available.
Second, it would be of interest to know the cause of death of
patients in both groups. The authors describe a nonsignificant
difference in myocardial infarction (MI) between users and non-
users (1.2% vs 2.1%). It might well be that a combined end point of
MI and cardiac death would have reached statistical significance.
A major point of concern in this paper is the inaccuracy of
reporting the number of patients and events and inconsequent
statistical analysis. For example, in the text the authors report 25
MIs, whereas Table II states that 27 patients had a MI. In case of
such a small number of events, that is, eight MIs in statin users and
19 in nonusers, these two cases might have a profound impact on
the P value. What if the number of MIs would be 6 (0.9%) vs 19
(2.1%)? Another flaw in the statistical analysis is the omission of
“contralateral carotid stenosis” in the multivariate analysis of peri-
operative death. In the “Methods” section, it is clearly stated that
the authors planned to include all covariables with P  .10 in the
multivariate analysis. Why didn’t the authors do so and would this
have an impact on the significance (P  .044) of the beneficial
effect of statin use?
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Reply
We want to thank Dr Kok for his interest in our work and
insightful comments. As Dr Kok points out, the literature with
respect to the potential clinical benefits of statin drugs is rapidly
growing, and it is clear that the efficacy of these agents extends well
beyond cholesterol-lowering and protection from coronary events.
Multiple medical trials have now demonstrated a significant reduc-
tion in long-term stroke incidence among patients with elevated
cholesterol levels, but nonstatin cholesterol-lowering therapies
have not resulted in such a reduction in stroke morbidity in this
patient population.
What is particularly intriguing is the observation that among
patients with normal cholesterol levels, statins have been associated
with a significant reduction in long-term stroke incidence.1 We
believe this strongly suggests that the lipid-independent pleiotro-
pic activities of statins are likely responsible for these clinical
observations. It is within this context that we sought to investigate
whether statin drug use might convey a protective effect in the
acute setting among patients undergoing carotid endarterectomy
(CEA), a highly effective stroke-preventing operation.
The pleiotropic effects of statins extend beyond plaque stabi-
lization and include improvements in endothelial function through
a nitric-oxide dependent process, as well as anti-inflammatory,
antithrombotic, and antioxidant activities. The incidence of peri-
operative stroke is lower among patients undergoing CEA for
asymptomatic vs symptomatic disease, but asymptomatic patients
still do experience perioperative strokes. In fact, there is growing
evidence that a percentage of patients with asymptomatic carotid
disease have experienced so-called silent strokes, as evident by
computed tomography or magnetic resonance imaging studies.2
And clearly, some patients with asymptomatic carotid stenoses may
have more unstable plaques than others. So, it is absolutely logical
and appropriate to include asymptomatic patients in our analysis.
We are well aware of the publication by Kennedy et al3 that
appeared in the literature several months after our data were
initially presented at the annual meeting of the Society for Vascular
Surgery. Their study differs from ours in that the beneficial effects
of statin therapy were only demonstrated among symptomatic
patients. Although plaque stabilization is an attractive hypothetical
explanation for the clinical benefit of statins among patients un-
dergoing CEA and may even reduce morbidity among clinically
asymptomatic patients with plaques at risk, the other pleiotropic
actions of statins may also be operative to some degree in both
asymptomatic and symptomatic patients. Moreover, it appears that
the majority of CEAs in contemporary practice are now performed
in asymptomatic patients. By including asymptomatic patients in
our study, we believe our analysis is more rigorous and our con-
clusions more generalizeable to the entire population of patients
with carotid stenosis than the Kennedy et al study.
The nature of our retrospective analysis, unfortunately, did not
allow us to determine with certainty the specific cause of mortality in
this decade-long experience. Although it is established in nonsurgical
patients that statins reduce cardiac mortality, our cohorts were heter-
ogeneous, with statin-users having considerably more cardiovascular
risk factors. Nevertheless, the incidence of 30-day myocardial infarc-
tion in statin users was lower (1.2% vs 2.1%), based on a total of 27
clinical events detailed in Table II. The relatively small number of
cardiac events in this study precluded this trend from having the
power to achieve statistical significance.And it isworthnoting that the
analysis of symptomatic patients by Kennedy et al3 similarly found no
statistically significant difference in the frequency of cardiac outcomes
between statin users and nonstatin users. But as Dr Kok surely knows,
we must be careful in our analysis of clinical outcome studies to
distinguish the difference between clinical and statistical significance.
With respect to the validity of our multivariate analysis, the
variable contralateral stenosis was indeed tested in this model but
did not reach statistical significance. Variables that trended towards
significance in univariate analysis were included in multivariate
analysis as described; however, any variable that did not achieve
significance in both the multivariate and univariate analysis was
removed from the final multivariate model. Contralateral stenosis
did not reach significance in univariate (P  .081) or multivariate
analysis (P  .32), thus it was taken out of the final model.
Furthermore, including contralateral stenosis in the multivariate
model does not change the four independent predictors of mor-
tality, which were carotid endarterectomy/coronary artery bypass
grafting, chronic renal insufficiency, atrial fibrillation, and statin
use. Thus, the impact of this variable does not affect the statistical
significance of statin use on mortality, and our conclusions remain
the same.
Our group is obviously excited about the novel findings of this
study and the implications for our patients. We believe that statin
use may represent a useful and logical strategy for making a very
effective and safe operation even better.
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Regarding “Evidence for early nasogastric
tube removal after infrarenal aortic surgery:
A randomized trial”
In view of the lack of objective data regarding nasogastric
decompression in aortic surgery, Goueffic’s group (J Vasc Surg
2005;42:654-9) have provided some useful information regarding
the practice. However, we feel that their data must be interpreted
with some care.
By their own admission, their series lacks sufficient power to
reliably establish equivalence between early and late withdrawal of
nasogastric decompression. They did demonstrate an increased
rate of respiratory complications, primarily pneumonia, in the late
removal group. Unfortunately, they provide no data regarding the
postoperative fluid management of their patients. To date, two
trials1,2 have reported the results of postoperative fluid restriction
vs “standard” fluid management with 1 liter of 0.9% saline and
2 liters of 5% dextrose per day in colorectal surgical patients. Lobo2
demonstrated a reduction in ileus, reduced length of stay, and
reduced risk of other complications. Brandstrup1 also reported a
lower risk of complications amongst the restricted arm of his trial,
including cardiopulmonary complications.
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